{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:02:05Z","timestamp":1753891325614,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Maintenance treatment can be recommended for patients with mycosis fungoides (MF) whose disease responds to primary treatment. While positive outcomes have been observed in small studies with maintenance therapy, there is a lack of practical guidelines and agreement on when and how maintenance therapy for MF should be approached. In this article, we discuss expert opinions and clinical experiences on the topic of maintenance therapy for patients with MF, with a focus on chlormethine gel. Ideally, patients should have a durable response before initiating maintenance therapy. The definition of and required duration of durable response are topics that are open to debate and currently have no consensus. Chlormethine gel has several attributes that make it suitable for maintenance therapy; it can be easily applied at home, can be combined with other treatment options for maintenance, and has a manageable safety profile. Chlormethine gel as maintenance therapy can be applied at decreasing frequencies after active treatment with chlormethine gel or other therapies until the minimally effective dose is reached. Patients generally tend to adhere well to chlormethine gel maintenance regimens and may remain on treatment for several years. The experiences described here may be useful for clinicians when deciding on maintenance treatment regimens for their patients. Development of guidelines based on clinical trial outcomes will be important to ensure the most effective maintenance treatment strategies are used for patients with MF.<\/jats:p>","DOI":"10.3389\/fmed.2023.1298988","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T14:52:44Z","timestamp":1705589564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Expert opinions and clinical experiences with chlormethine gel as maintenance treatment for patients with mycosis fungoides"],"prefix":"10.3389","volume":"10","author":[{"given":"Larisa","family":"Geskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neda","family":"Nikbakht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ardig\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Wehkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"ESMO guidelines committee. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1007\/s13555-022-00831-w","article-title":"Maintenance and concomitant therapy use with chlormethine gel among patients with stage IA\/IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a real-world evidence study","volume":"12","author":"Querfeld","year":"2022","journal-title":"Dermathol Ther (Heidelb)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/ddg.14688","article-title":"The optimal use of chlormethine gel for mycosis fungoides: an expert consensus from Germany, Austria and Switzerland (DACH region)","volume":"20","author":"Assaf","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"year":"2023","key":"ref5"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaad.2005.03.012","article-title":"Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides","volume":"53","author":"Boztepe","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/jamadermatol.2018.5905","article-title":"Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: a randomized clinical trial","volume":"155","author":"Vieyra-Garcia","year":"2019","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/ddg.14657","article-title":"Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma","volume":"20","author":"Elsayad","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjd.20757","article-title":"Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides","volume":"186","author":"Falkenhain-L\u00f3pez","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.det.2019.08.013","article-title":"Phototherapy for cutaneous T-cell lymphoma","volume":"38","author":"Marka","year":"2020","journal-title":"Dermatol Clin"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clml.2020.11.022","article-title":"Evaluating the treatment patterns of chlormethine\/mechlorethamine gel in patients with stage I-IIA mycosis fungoides: by-time reanalysis of a randomized controlled phase 2 study","volume":"21","author":"Geskin","year":"2021","journal-title":"Clin Lymph Myel Leuk"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the United States cutaneous lymphoma consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/s0190-9622(88)70223-6","article-title":"Topical mechlorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsay","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/1097-0142(19831215)52:12<2214::aid-cncr2820521207>3.0.co;2-h","article-title":"Ointment-based mechlorethamine treatment for mycosis fungoides","volume":"52","author":"Price","year":"1983","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ejca.2007.06.015","article-title":"Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?","volume":"43","author":"Dummer","year":"2007","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0360-3016(98)00517-3","article-title":"Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides","volume":"43","author":"Chinn","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1067\/mjd.2003.449","article-title":"Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma","volume":"49","author":"Duvic","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"year":"2020","key":"ref19"},{"year":"2020","key":"ref20"},{"year":"2017","key":"ref21"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1007\/s12325-022-02219-w","article-title":"Chlormethine gel for patients with mycosis fungoides cutaneous T cell lymphoma: a review of efficacy and safety in clinical trial and real-world settings","volume":"39","author":"Wehkamp","year":"2022","journal-title":"Adv Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jid.2020.12.009","article-title":"Lack of systemic absorption of topical mechlorethamine gel in patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"141","author":"Querfeld","year":"2021","journal-title":"J Invest Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","article-title":"The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"22","author":"Kim","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1080\/09546634.2021.1967266","article-title":"Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects","volume":"33","author":"Prag Naveh","year":"2022","journal-title":"J Dermatol Treat"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/jdv.18183","article-title":"Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice","volume":"36","author":"Papadavid","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/ddg.14462_g","article-title":"Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers","volume":"19","author":"Wehkamp","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.clml.2022.02.002","article-title":"Response to chlormethine\/mechlorethamine gel maintenance treatment regimen in patients with mycosis fungoides: a single-center retrospective study","volume":"22","author":"Correia","year":"2022","journal-title":"Clin Lymph Myel Leuk"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"adv00862","DOI":"10.2340\/actadv.v103.4881","article-title":"Prior bexarotene or phototherapy does not affect response to chlormethine gel: post hoc analysis of a pivotal trial","volume":"103","author":"Assaf","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"adv00544","DOI":"10.2340\/00015555-3911","article-title":"Management of mycosis fungoides with topical chlormethine\/mechlorethamine gel: a Columbia University Cutaneous Lymphoma Center experience","volume":"101","author":"Garcia-Saleem","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref33","first-page":"25","article-title":"Maintenance phototherapy for the treatment of early-stage mycosis fungoides","volume":"14","author":"Gara","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jdcr.2020.05.031","article-title":"Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis","volume":"6","author":"Gilmore","year":"2020","journal-title":"JAAD Case Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1298988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T14:52:47Z","timestamp":1705589567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1298988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":34,"alternative-id":["10.3389\/fmed.2023.1298988"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1298988","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"article-number":"1298988"}}